Click for best price
SERD Selective Estrogen Receptor Degrader Drugs Market Size, Share 2022
This report contains market size and forecasts of SERD (Selective Estrogen Receptor Degrader) Drugs in Global, including the following market information:
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global SERD (Selective Estrogen Receptor Degrader) Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
RAD1901 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of SERD (Selective Estrogen Receptor Degrader) Drugs include Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr. Reddy's Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG and InventisBio, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We has surveyed the SERD (Selective Estrogen Receptor Degrader) Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Segment Percentages, by Type, 2021 (%)
RAD1901
GDC-9545
AZD9833
SAR439859
Faslodex
Others
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Segment Percentages, by Application, 2021 (%)
First-Line Treatment
Second-Line Treatment
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies SERD (Selective Estrogen Receptor Degrader) Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies SERD (Selective Estrogen Receptor Degrader) Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amneal Pharmaceuticals Inc
AstraZeneca, Plc.
Dr. Reddy's Laboratories
Eli Lilly and Company
G1 Therapeutics, Inc.
Glenmark Pharmaceuticals
HBT Labs, Inc
Hoffmann-La Roche AG
InventisBio
Novartis AG
Radius Health
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Zenopharm LLC.
Zentalis Pharmaceuticals
| Report Attributes |
Report Details |
| Report Title |
SERD (Selective Estrogen Receptor Degrader) Drugs Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
109 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 SERD (Selective Estrogen Receptor Degrader) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Overall Market Size
2.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size: 2021 VS 2028
2.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top SERD (Selective Estrogen Receptor Degrader) Drugs Players in Global Market
3.2 Top Global SERD (Selective Estrogen Receptor Degrader) Drugs Companies Ranked by Revenue
3.3 Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue by Companies
3.4 Top 3 and Top 5 SERD (Selective Estrogen Receptor Degrader) Drugs Companies in Global Market, by Revenue in 2021
3.5 Global Companies SERD (Selective Estrogen Receptor Degrader) Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 SERD (Selective Estrogen Receptor Degrader) Drugs Players in Global Market
3.6.1 List of Global Tier 1 SERD (Selective Estrogen Receptor Degrader) Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 SERD (Selective Estrogen Receptor Degrader) Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Markets, 2021 & 2028
4.1.2 RAD1901
4.1.3 GDC-9545
4.1.4 AZD9833
4.1.5 SAR439859
4.1.6 Faslodex
4.1.7 Others
4.2 By Type - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue & Forecasts
4.2.1 By Type - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, 2017-2022
4.2.2 By Type - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, 2023-2028
4.2.3 By Type - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2021 & 2028
5.1.2 First-Line Treatment
5.1.3 Second-Line Treatment
5.2 By Application - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue & Forecasts
5.2.1 By Application - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, 2017-2022
5.2.2 By Application - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, 2023-2028
5.2.3 By Application - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2021 & 2028
6.2 By Region - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue & Forecasts
6.2.1 By Region - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, 2017-2022
6.2.2 By Region - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, 2023-2028
6.2.3 By Region - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, 2017-2028
6.3.2 US SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.3.3 Canada SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.3.4 Mexico SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, 2017-2028
6.4.2 Germany SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.4.3 France SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.4.4 U.K. SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.4.5 Italy SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.4.6 Russia SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.4.7 Nordic Countries SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.4.8 Benelux SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, 2017-2028
6.5.2 China SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.5.3 Japan SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.5.4 South Korea SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.5.5 Southeast Asia SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.5.6 India SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, 2017-2028
6.6.2 Brazil SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.6.3 Argentina SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, 2017-2028
6.7.2 Turkey SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.7.3 Israel SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.7.4 Saudi Arabia SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
6.7.5 UAE SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, 2017-2028
7 Players Profiles
7.1 Amneal Pharmaceuticals Inc
7.1.1 Amneal Pharmaceuticals Inc Corporate Summary
7.1.2 Amneal Pharmaceuticals Inc Business Overview
7.1.3 Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.1.4 Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.1.5 Amneal Pharmaceuticals Inc Key News
7.2 AstraZeneca, Plc.
7.2.1 AstraZeneca, Plc. Corporate Summary
7.2.2 AstraZeneca, Plc. Business Overview
7.2.3 AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.2.4 AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.2.5 AstraZeneca, Plc. Key News
7.3 Dr. Reddy's Laboratories
7.3.1 Dr. Reddy's Laboratories Corporate Summary
7.3.2 Dr. Reddy's Laboratories Business Overview
7.3.3 Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.3.4 Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.3.5 Dr. Reddy's Laboratories Key News
7.4 Eli Lilly and Company
7.4.1 Eli Lilly and Company Corporate Summary
7.4.2 Eli Lilly and Company Business Overview
7.4.3 Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.4.4 Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.4.5 Eli Lilly and Company Key News
7.5 G1 Therapeutics, Inc.
7.5.1 G1 Therapeutics, Inc. Corporate Summary
7.5.2 G1 Therapeutics, Inc. Business Overview
7.5.3 G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.5.4 G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.5.5 G1 Therapeutics, Inc. Key News
7.6 Glenmark Pharmaceuticals
7.6.1 Glenmark Pharmaceuticals Corporate Summary
7.6.2 Glenmark Pharmaceuticals Business Overview
7.6.3 Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.6.4 Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.6.5 Glenmark Pharmaceuticals Key News
7.7 HBT Labs, Inc
7.7.1 HBT Labs, Inc Corporate Summary
7.7.2 HBT Labs, Inc Business Overview
7.7.3 HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.7.4 HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.7.5 HBT Labs, Inc Key News
7.8 Hoffmann-La Roche AG
7.8.1 Hoffmann-La Roche AG Corporate Summary
7.8.2 Hoffmann-La Roche AG Business Overview
7.8.3 Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.8.4 Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.8.5 Hoffmann-La Roche AG Key News
7.9 InventisBio
7.9.1 InventisBio Corporate Summary
7.9.2 InventisBio Business Overview
7.9.3 InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.9.4 InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.9.5 InventisBio Key News
7.10 Novartis AG
7.10.1 Novartis AG Corporate Summary
7.10.2 Novartis AG Business Overview
7.10.3 Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.10.4 Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.10.5 Novartis AG Key News
7.11 Radius Health
7.11.1 Radius Health Corporate Summary
7.11.2 Radius Health Business Overview
7.11.3 Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.11.4 Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.11.5 Radius Health Key News
7.12 Sanofi S.A.
7.12.1 Sanofi S.A. Corporate Summary
7.12.2 Sanofi S.A. Business Overview
7.12.3 Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.12.4 Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.12.5 Sanofi S.A. Key News
7.13 Teva Pharmaceutical Industries Ltd.
7.13.1 Teva Pharmaceutical Industries Ltd. Corporate Summary
7.13.2 Teva Pharmaceutical Industries Ltd. Business Overview
7.13.3 Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.13.4 Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.13.5 Teva Pharmaceutical Industries Ltd. Key News
7.14 Zenopharm LLC.
7.14.1 Zenopharm LLC. Corporate Summary
7.14.2 Zenopharm LLC. Business Overview
7.14.3 Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.14.4 Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.14.5 Zenopharm LLC. Key News
7.15 Zentalis Pharmaceuticals
7.15.1 Zentalis Pharmaceuticals Corporate Summary
7.15.2 Zentalis Pharmaceuticals Business Overview
7.15.3 Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Major Product Offerings
7.15.4 Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global Market (2017-2022)
7.15.5 Zentalis Pharmaceuticals Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. SERD (Selective Estrogen Receptor Degrader) Drugs Market Opportunities & Trends in Global Market
Table 2. SERD (Selective Estrogen Receptor Degrader) Drugs Market Drivers in Global Market
Table 3. SERD (Selective Estrogen Receptor Degrader) Drugs Market Restraints in Global Market
Table 4. Key Players of SERD (Selective Estrogen Receptor Degrader) Drugs in Global Market
Table 5. Top SERD (Selective Estrogen Receptor Degrader) Drugs Players in Global Market, Ranking by Revenue (2021)
Table 6. Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Share by Companies, 2017-2022
Table 8. Global Companies SERD (Selective Estrogen Receptor Degrader) Drugs Product Type
Table 9. List of Global Tier 1 SERD (Selective Estrogen Receptor Degrader) Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 SERD (Selective Estrogen Receptor Degrader) Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2023-2028
Table 30. Amneal Pharmaceuticals Inc Corporate Summary
Table 31. Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 32. Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
Table 33. AstraZeneca, Plc. Corporate Summary
Table 34. AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 35. AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
Table 36. Dr. Reddy's Laboratories Corporate Summary
Table 37. Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 38. Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
Table 39. Eli Lilly and Company Corporate Summary
Table 40. Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 41. Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
Table 42. G1 Therapeutics, Inc. Corporate Summary
Table 43. G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 44. G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
Table 45. Glenmark Pharmaceuticals Corporate Summary
Table 46. Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 47. Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
Table 48. HBT Labs, Inc Corporate Summary
Table 49. HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 50. HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
Table 51. Hoffmann-La Roche AG Corporate Summary
Table 52. Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 53. Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
Table 54. InventisBio Corporate Summary
Table 55. InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 56. InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
Table 57. Novartis AG Corporate Summary
Table 58. Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 59. Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
Table 60. Radius Health Corporate Summary
Table 61. Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 62. Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
Table 63. Sanofi S.A. Corporate Summary
Table 64. Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 65. Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
Table 66. Teva Pharmaceutical Industries Ltd. Corporate Summary
Table 67. Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 68. Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
Table 69. Zenopharm LLC. Corporate Summary
Table 70. Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 71. Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
Table 72. Zentalis Pharmaceuticals Corporate Summary
Table 73. Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Product Offerings
Table 74. Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. SERD (Selective Estrogen Receptor Degrader) Drugs Segment by Type in 2021
Figure 2. SERD (Selective Estrogen Receptor Degrader) Drugs Segment by Application in 2021
Figure 3. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in 2021
Figure 8. By Type - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share, 2017-2028
Figure 9. By Application - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share, 2017-2028
Figure 10. By Region - Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share, 2017-2028
Figure 11. By Country - North America SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share, 2017-2028
Figure 12. US SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 13. Canada SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share, 2017-2028
Figure 16. Germany SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 17. France SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 19. Italy SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Russia SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share, 2017-2028
Figure 24. China SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. Japan SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. India SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share, 2017-2028
Figure 30. Brazil SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share, 2017-2028
Figure 33. Turkey SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Israel SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. UAE SERD (Selective Estrogen Receptor Degrader) Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
